Reata Pharmaceuticals, Inc.
Symbol: RETA
NASDAQ
172.36
USDDzisiejsza cena rynkowa
-89.3629
Wskaźnik P/E
0.0000
Wskaźnik PEG
6.57B
Kapitalizacja MRK
- 0.00%
Rentowność DIV
Reata Pharmaceuticals, Inc. (RETA) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1474.56 | 387.5 | 590.3 | 818.1 | ||||||||||
balance-sheet.row.short-term-investments | 1266.55 | 345.2 | 0 | 0 | ||||||||||
balance-sheet.row.net-receivables | 16.95 | 0 | 0 | 22.2 | ||||||||||
balance-sheet.row.inventory | 8.65 | 0 | 0 | -22.2 | ||||||||||
balance-sheet.row.other-current-assets | 77.1 | 10.3 | 6.2 | 29.2 | ||||||||||
balance-sheet.row.total-current-assets | 1577.27 | 397.8 | 596.5 | 847.3 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 459.6 | 116.4 | 138.4 | 4.9 | ||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 17.44 | 0.3 | 0.2 | 5.3 | ||||||||||
balance-sheet.row.total-non-current-assets | 477.04 | 116.7 | 138.5 | 10.3 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 2054.3 | 514.5 | 735 | 857.6 | ||||||||||
balance-sheet.row.account-payables | 60.53 | 18.7 | 13.5 | 4.8 | ||||||||||
balance-sheet.row.short-term-debt | 13.07 | 2.2 | 3.1 | 87.5 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 534.25 | 117.3 | 136 | 0 | ||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 4.7 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 131.23 | 38.1 | 35.7 | 22.3 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 1869.5 | 521.2 | 495 | 321 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 470.98 | 119.5 | 136 | 0 | ||||||||||
balance-sheet.row.total-liab | 2158.86 | 580.2 | 549 | 440.2 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0.15 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -6223.86 | -1567.5 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 4566.18 | 1501.8 | 0 | 0 | ||||||||||
balance-sheet.row.total-stockholders-equity | -1657.54 | -65.7 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 501.33 | 514.5 | -706.6 | -518.1 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | -1657.54 | -65.7 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 501.33 | - | - | - | ||||||||||
Total Investments | 1266.55 | 345.2 | 0 | 0 | ||||||||||
balance-sheet.row.total-debt | 544.11 | 119.5 | 136 | 0 | ||||||||||
balance-sheet.row.net-debt | 336.1 | 77.2 | -454.2 | -818.1 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -87.62 | -311.9 | -297.4 | -247.8 | ||||||||||
cash-flows.row.depreciation-and-amortization | 1.13 | 1.1 | 1.2 | 1.1 | ||||||||||
cash-flows.row.deferred-income-tax | -291.96 | 0 | 0 | 11.2 | ||||||||||
cash-flows.row.stock-based-compensation | 87.84 | 58.7 | 56.8 | 57.6 | ||||||||||
cash-flows.row.change-in-working-capital | 7.84 | 9.3 | -49.6 | -172.7 | ||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.inventory | -13.28 | 0 | 0 | 0 | ||||||||||
cash-flows.row.account-payables | 11.97 | 5.2 | 8.7 | 2.9 | ||||||||||
cash-flows.row.other-working-capital | 9.16 | 4.1 | -58.3 | -175.6 | ||||||||||
cash-flows.row.other-non-cash-items | 34.44 | 38.5 | 53.3 | 28.1 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -248.34 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.12 | -3.3 | -1.3 | -0.9 | ||||||||||
cash-flows.row.acquisitions-net | 75 | 0 | 0 | 0 | ||||||||||
cash-flows.row.purchases-of-investments | -631.88 | -661.9 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 617.42 | 320 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 59.42 | -345.2 | -1.3 | -0.9 | ||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | -167.2 | ||||||||||
cash-flows.row.common-stock-issued | 222.73 | 0 | 333.3 | 333.3 | ||||||||||
cash-flows.row.common-stock-repurchased | 22.65 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-financing-activites | -231.54 | 1.5 | -324.1 | 311 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 90.61 | 1.5 | 9.1 | 477.1 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 167.98 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -98.31 | -547.9 | -227.9 | 153.8 | ||||||||||
cash-flows.row.cash-at-end-of-period | 208.01 | 42.3 | 590.3 | 818.1 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 306.32 | 590.3 | 818.1 | 664.3 | ||||||||||
cash-flows.row.operating-cash-flow | -248.34 | -204.3 | -235.7 | -322.3 | ||||||||||
cash-flows.row.capital-expenditure | -1.12 | -3.3 | -1.3 | -0.9 | ||||||||||
cash-flows.row.free-cash-flow | -249.46 | -207.5 | -237 | -323.3 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 24.39 | 2.2 | 11.5 | 9 | ||||||||||
income-statement-row.row.cost-of-revenue | 0.85 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.gross-profit | 23.55 | 2.2 | 11.5 | 9 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 203.31 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 114.18 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0.73 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.operating-expenses | 364.3 | 280.3 | 256.2 | 235.3 | ||||||||||
income-statement-row.row.cost-and-expenses | 365.15 | 280.3 | 256.2 | 235.3 | ||||||||||
income-statement-row.row.interest-income | 0 | 6 | 0.2 | 0 | ||||||||||
income-statement-row.row.interest-expense | 40.61 | 41.8 | 53.3 | 36.8 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | 253.97 | -41.8 | -53.1 | -43.9 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0.73 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.total-operating-expenses | 253.97 | -41.8 | -53.1 | -43.9 | ||||||||||
income-statement-row.row.interest-expense | 40.61 | 41.8 | 53.3 | 36.8 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 1.13 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.ebitda-caps | -332.65 | - | - | - | ||||||||||
income-statement-row.row.operating-income | -59.48 | -270.2 | -244.7 | -226.3 | ||||||||||
income-statement-row.row.income-before-tax | -87.68 | -311.9 | -297.8 | -270.2 | ||||||||||
income-statement-row.row.income-tax-expense | 0.25 | 0 | -0.5 | -22.5 | ||||||||||
income-statement-row.row.net-income | -80.06 | -311.9 | -297.4 | -247.8 |
Często zadawane pytania
Ile wynosi Reata Pharmaceuticals, Inc. (RETA) aktywów ogółem?
Reata Pharmaceuticals, Inc. (RETA) całkowite aktywa to 514491000.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 22941000.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.965.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to -6.010.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to -3.282.
Jaki jest całkowity przychód firmy?
Całkowity przychód to -2.438.
Co to jest Reata Pharmaceuticals, Inc. (RETA) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi -311901000.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 119464000.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 280250000.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 48843000.000.